Novonesis Group

Denmark · owned by Independent (Denmark) · www.novonesis.com · 20 vendors

Novonesis is a leading global biosolutions company formed through the combination of Chr. Hansen and Novozymes in 2024. The company leverages microbiology and enzymes to develop and manufacture biosolutions across more than 30 industries, including food and beverages, human health, household care, bioenergy, and agriculture. With approximately 11,000 employees worldwide, Novonesis helps customers produce and consume more sustainably by replacing chemical and fossil-based inputs with biological alternatives.

Resilience scores

Technology vendors

Insights

Last updated 2026-09-12 · revision 7

20 direct vendors, 255 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 6/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

Novonesis Group exhibits medium migration readiness, primarily driven by a modern tech stack but tempered by significant regulatory and data residency complexities. The internal tech stack is highly conducive to migration, featuring extensive adoption of cloud services (Microsoft Azure, Azure Data Lake, Databricks, Azure DevOps) and modern SaaS platforms (Salesforce, ServiceNow), alongside a modern ERP (SAP S/4HANA). This indicates a strong foundation for cloud-native architectures, containerization, and microservices adoption, facilitating easier transitions. The company's strong financial stability, evidenced by substantial revenue growth, suggests it has the resources to fund complex migration projects. Vendor relationships show geographic diversity across 7 HQ countries, which could mitigate some vendor-specific lock-in risks. However, the 'Vendor Lock-in Risk' is explicitly 'Unknown,' which is a critical blind spot that could complicate migration efforts if deeply embedded, difficult-to-replace vendor solutions exist. The most significant challenge to migration readiness stems from the regulatory environment and data residency requirements. GDPR and NIS2 compliance are 'Assessment Required,' meaning the current state of compliance is unknown, and any migration must meticulously ensure adherence to these regulations. Crucially, as a Danish company, Novonesis Group must comply with GDPR data residency requirements, mandating that personal data of EU residents be processed within the EU/EEA or in countries with adequacy decisions, requiring careful planning for data flows and storage locations in any cloud migration scenario. These regulatory and data residency constraints will add considerable complexity, cost, and time to any large-scale migration initiative.

Compliance

11 in-scope frameworks identified; showing 3.

REACH — Assessment Required

Novonesis manufactures and places chemical substances (enzymes) on the EU market, making REACH compliance mandatory.

As a manufacturer of enzymes, which are chemical substances, non-compliance with REACH could result in significant fines and market access restrictions in the EU. The risk is high due to the complexity of the regulation and the nature of their products.

Evidence: https://www.khlaw.com/insights/navigating-food-approvals-china-ingredients-and-additives-finished-foods, https://www.norceresearch.no/en/news/focusing-on-risks-not-hazards-can-pave-the-way-for-smaller-enzyme-producers, https://amfep.org/about-enzymes/regulatory/technical-enzymes-regulations/, https://amfep.org/_library/_files/ERC-guidance-on-REACH-registration.pdf

EU Feed Additives Regulation — Compliant

Novonesis develops, manufactures, and sells enzymes for use in animal feed within the EU, making them subject to this regulation.

Non-compliance would prevent market access for their feed additive products in the EU. The risk is medium as the company has a clear track record of successfully navigating the approval process.

Evidence: https://www.khlaw.com/insights/navigating-food-approvals-china-ingredients-and-additives-finished-foods, https://www.norceresearch.no/en/news/focusing-on-risks-not-hazards-can-pave-the-way-for-smaller-enzyme-producers, https://amfep.org/_library/_files/ERC-guidance-on-REACH-registration.pdf, https://food.ec.europa.eu/food-safety/animal-feed/feed-additives/legislation-feed-additives_en, https://www.agindustries.org.uk/resource/feed-additives-legislation.html, https://www.argentaglobal.com/post/feed-additives-new-guidance-documents

China's 'Three New Foods' Regulations — Assessment Required

With a regional headquarters, R&D, and manufacturing in China, Novonesis is subject to China's regulations for new food ingredients, additives, and packaging materials when introducing new products to the Chinese market.

Market access to China for new food ingredients and additives is contingent on compliance. The risk is medium, as the company has a significant presence and R&D in China, suggesting experience with the local regulatory landscape.

Evidence: https://www.khlaw.com/insights/navigating-food-approvals-china-ingredients-and-additives-finished-foods, https://www.proregulations.com/china-novel-food-ingredients-compliance.html, https://www.norceresearch.no/en/news/focusing-on-risks-not-hazards-can-pave-the-way-for-smaller-enzyme-producers, https://www.biosafe.fi/insight/the-eus-stance-on-genetically-modified-microorganisms-gmms, https://www.zmuni.com/en/service/2237/, https://en.reach24h.com/news/industry-news/food/china-three-new-foods-regulatory-framework-approvals

Financials

Three-year financials

Financial Resilience Score: 8/10

Novonesis demonstrates strong financial resilience as the global #1 player in enzymes and microbial cultures following the January 2024 merger of Novozymes and Chr. Hansen. The combined entity benefits from adjusted EBIT margins of ~25-27%, among the strongest in specialty industrial biotech, supported by proprietary strain and enzyme IP that creates structural pricing power. Gross margins are protected by high switching costs as products are embedded in customers' continuous production processes across detergents, dairy cultures, baking, and animal feed. The balance sheet is solid with an investment-grade-style profile. While leverage rose to finance the merger, cash conversion remains strong (legacy Novozymes generated >DKK 3B in free cash flow). Equity stepped up dramatically at merger close to ~DKK 80B+ from the issuance of ~366 million new B-shares to former Chr. Hansen shareholders. Anchor ownership by Novo Holdings A/S (Novo Nordisk Foundation) provides long-term stability. Revenue diversification across food & beverage, household care, agriculture, bioenergy, and human/animal health markets limits cyclicality. Management targets 6-8% organic revenue growth annually with adjusted EBIT margin expansion toward high-20s%. Key risks include integration execution, customer concentration in household care (P&G, Unilever, Henkel), bioenergy cyclicality, FX exposure (DKK reporting vs USD/EUR revenue), and significant PPA amortization drag on reported earnings.

Key strengths: Global #1 position in enzymes and microbial cultures post-merger, Adjusted EBIT margins of ~25-27%, top-tier in specialty biotech, Diversified end-markets across food, household care, agriculture, bioenergy, Recurring revenue character with sticky customer demand, Strong free cash flow generation (>DKK 3B historically at Novozymes), Anchor shareholder Novo Holdings A/S providing long-term stability, Proprietary strain and enzyme IP creating defensible moat

Risk factors: Integration execution risk from combining two large organizations, Customer concentration in household care (P&G, Unilever, Henkel), Bioenergy/ethanol demand cyclicality and policy dependence, FX risk: DKK reporting vs USD/EUR/EM currency revenues, PPA amortization drag on reported EBIT and net income for years, Agriculture/BioAg partnerships underperforming initial expectations, Elevated leverage post-merger requiring deleveraging

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report